Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2020, with the report dated October 22, 2020. The document serves as a notification of major holdings pursuant to UK Disclosure and Transparency Rules (DTR), specifically reporting a change in voting rights held by a significant shareholder.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a regulatory notification regarding share ownership and does not contain financial performance data.
Material Changes Versus Prior Period
The filing reports a material change in the voting rights held by The Capital Group Companies, Inc. (CGC) and its affiliates:
- Previous Position: 5.0803% of voting rights.
- Current Position (as of Oct 20, 2020): 4.9865% of voting rights.
- Change: A decrease of approximately 0.0938% in total voting rights.
- Share Count: The total number of voting rights held is 250,190,943 out of 5,017,375,238 total voting rights of the issuer.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding GSK's business operations. The document includes additional information clarifying that CGC does not own shares for its own account; rather, the reported shares are owned by accounts under the discretionary investment management of its affiliates, including Capital Research and Management Company and Capital Bank & Trust Company.
Important Facts for Investor Verification
- Verify the exact date the threshold was crossed (October 20, 2020) and the notification date (October 21, 2020).
- Confirm the breakdown of holdings between Common Stock (GB0009252882) and Depository Receipts (US37733W1053).
- Note that the reduction in stake brought the holding below the 5% notification threshold previously held.
- Understand that the reported shares are held on behalf of mutual funds and institutional clients, not for the parent company's own account.